ERBB2 and gastric cancer: These findings highlight some of the challenges of HER2 expression as a predictive biomarker due to the spatial and temporal intratumour heterogeneity of HER2, the lack of standardised and site-specific scoring systems beyond breast and gastric cancer, as well as the impact of concomitant oncogenic drivers on ADC activity [29].